Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation
Status:
Completed
Trial end date:
2021-08-03
Target enrollment:
Participant gender:
Summary
This is a single-arm, non-randomized multicentre phase 2 study in NSCLC patients with EGFR
exon 20 insertion mutation, whose disease has progressed on standard chemotherapy.